Barclays downgraded Moderna (NASDAQ: MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of ...

The Texas Department of State Health Services canceled its biennial immunization conference amid uncertainty over CDC ...

Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today ...

The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss.

The more tempered approach comes as Moderna prepares to announce full-year 2024 results this month that will include sales of its flagship COVID-19 vaccine Spikevax, which like all COVID products ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax, following in the footsteps of Pfizer/BioNTech, which filed their Comirnaty shot ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

Moreover, Thermo Fisher Scientific’s ongoing and long-term strategic collaboration with Moderna aims to enable dedicated large-scale manufacturing in the US of Spikevax, Moderna’s COVID-19 ...

1 Pfizer-BioNTech/Comirnaty and JN.1 Moderna/Spikevax vaccines, which continue to be free under the programme. Both are mRNA vaccines. In December, MOH said those who wanted to get the Novavax ...